The next wave of protease inhibitors.

  • Theo Smart
  • Published 1995 in
    GMHC treatment issues : the Gay Men's Health…


Three new protease inhibitors stand out in light of cross-resistance, either because they achieve levels in the blood that may overwhelm low-level resistance, or because data suggest that they will not be cross-resistant with compounds in current clinical trials. Agouron has released information from its first patient (Patient 001) to a complete phase I… (More)


  • Presentations referencing similar topics